Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthCapital Bluecross rTMS Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy BH-159 (05/27/25)

    Repetitive Transcranial Magnetic Stimulation (rTMS) Request Form and Clinical Criteria

    Customize your policy alerts

    Sign up for Capital Bluecross Policy BH-159 (05/27/25) alerts

    Get alerted when Policy BH-159 (05/27/25) changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is a preauthorization request form and clinical criteria checklist governing rTMS treatment requests for Capital Blue Cross members, used by providers to document diagnosis, prior treatments, and medical necessity for coverage decisions.

    Policy Summary
    PayerCapital Bluecross
    PolicyRepetitive Transcranial Magnetic Stimulation (rTMS) Request Form and Clinical Criteria
    Policy CodePolicy BH-159 (05/27/25)
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit the completed rTMS request form with member/provider details, confirmed diagnosis (F32.2 or F33.2), pre‑treatment rating scale scores, detailed prior medication trials, and requested CPT code(s) for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2+min antidepressant trials
    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    alternate threshold
    90867-90869CPT codes
    717.346.5800fax
    800.471.2242preauth phone

    Coverage Criteria for rTMS

    Capital clinical vignette Criteria for medical necessity

    Alternate Capital clinical vignette criteria — any ONE of the following may support medical necessity:

    Clinical vignette alternate criteria: Resistance to treatment with pharmacological agents as evidenced by lack of response to four trials from two agent classes OR lack of response to three trials from two agent classes plus one augmenting agent OR inability to tolerate pharmacological agents as evidenced by trials of four such agents with distinct side effects OR history of positive response to prior TMS within the past six months OR currently receiving ECT and TMS is considered a less invasive alternative.see text

    These are presented as alternative routes to establish medical necessity in the vignette section.

    The following conditions are exclusionary for coverage of rTMS and must be absent for medical necessity: active substance use disorder or eating disorder within the past year; recent history of obsessive–compulsive disorder or post‑traumatic stress disorder; recent history of a psychotic disorder (including schizoaffective disorder), bipolar disease, or major depression with psychotic features; diagnosis of MDD in the context of a current or past manic, mixed, or hypomanic episode; presence of a suicide plan or recent suicide attempt; neurological contraindications such as epilepsy, cerebrovascular disease, dementia, Parkinson’s disease, multiple sclerosis, increased intracranial pressure, history of repetitive or severe head trauma, or primary/secondary CNS tumor; and presence of vagus nerve stimulator leads in the carotid sheath.

    rTMS is considered not medically necessary when any of the exclusionary medical or psychiatric conditions listed above are present. In addition, the treating physician must have examined the member, reviewed the record, demonstrate experience administering rTMS, and directly supervise the procedure on site and be immediately available; lack of these supervision/order requirements will render services non‑covered.

    Diagnosis and Procedure Codes

    Covered ICD-10 Diagnoses (form options)ICD-10Covered
    F32.2Major Depressive Disorder, Single Episode, Severe (Without Psychotic Features)
    F33.2Major Depressive Disorder, Recurrent Episode, Severe (Without Psychotic Features)
    Requested CPT CodesCPT
    90867Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment - initial, including cortical mapping, motor threshold determination, and delivery and management
    90868Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment - subsequent delivery and management, per session
    90869Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment - subsequent motor threshold redetermination with delivery and management
    Required prior medication trials
    Standard requirementMinimum of two adequate trials of psychopharmacologic agents (each ≥6 weeks at adequate dose) from at least two different medication classes in the current depressive episode, documented with standardized rating scales.
    Vignette alternative — four trialsLack of response to four trials from two agent classes (alternative pathway to establish resistance per clinical vignette).
    Vignette alternative — three trials + augmentationLack of response to three trials from two agent classes plus one augmenting agent (alternative pathway per vignette).
    Intolerance pathwayInability to tolerate medications as evidenced by trials of four pharmacologic agents with distinct side effects (acceptable alternative to resistance trials).
    Documentation expectationsDetailed prior medication trial documentation required: medication name, dosage, dates, and comments on response/tolerance (provided on the form).

    Provider Requirements and Authorization Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for rTMS. Submit the completed Magnetic Stimulation (rTMS) Request Form and any supplemental documentation to Capital Blue Cross Preauthorization (fax: 717.346.5800). For questions contact Preauthorization at 800.471.2242.

    • Use the rTMS request form; indicate the FDA-approved device and requested CPT code(s) (e.g., 90867, 90868, 90869).
    • Include proposed start date and number of units/sessions.
    • Provider ordering must be a physician who has examined the member, reviewed the record, has experience administering rTMS, and directly supervises the procedure (on-site and immediately available).
    Step Therapy

    Step Therapy / Prior Medication Requirements

    Document prior adequate pharmacologic therapy trials. rTMS is indicated for treatment-resistant major depressive disorder after adequate medication trials unless other clinical criteria (e.g., intolerance, prior positive TMS response) apply.

    Level of Care Settings

    Treatment Modalities

    TMS

    TMS modality requirements: Use of an FDA-approved TMS device and selection of the appropriate CPT code for the requested service (90867 for initial including cortical mapping and motor threshold determination; 90868 for subsequent delivery per session; 90869 for motor threshold redetermination) as indicated on the request form.see text

    Device and CPT code must be specified on the form.

    Key Definitions

    treatment-resistant depression (definition)
    DefinitionTreatment-resistant depression is operationalized on the form as inadequate clinical response to psychopharmacologic treatment — typically failure of at least two adequate trials from different medication classes in the current depressive episode, each of at least six weeks' duration and documented by standardized rating scales.
    Alternative definitions (vignette)Also may be defined by lack of response to four trials from two agent classes, or three trials from two classes plus one augmenting agent, or intolerance to four distinct agents — these are presented as alternate routes to establish medical necessity.
    Clinical confirmationDiagnosis must be severe MDD (F32.2 or F33.2) with documented pre-treatment rating scale score and treating physician review, per initial treatment criteria.
    CPT codes for rTMS services
    90867Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment - initial, including cortical mapping, motor threshold determination, and delivery and management.

    Background

    Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive, device‑based neuromodulation treatment used for individuals with treatment‑resistant major depressive disorder (MDD). The request form requires documentation that the member meets severe MDD diagnostic criteria and that alternative treatments have been considered or tried. Clinical eligibility hinges on demonstration of inadequate response to pharmacologic therapy or inability to tolerate medications, absence of exclusionary neurologic or psychiatric conditions, measurement of baseline depressive symptom severity with a standardized rating scale, and direct on‑site supervision by a physician experienced in rTMS.

    Policy Summary
    PayerCapital Bluecross
    PolicyRepetitive Transcranial Magnetic Stimulation (rTMS) Request Form and Clinical Criteria
    Policy CodePolicy BH-159 (05/27/25)
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit the completed rTMS request form with member/provider details, confirmed diagnosis (F32.2 or F33.2), pre‑treatment rating scale scores, detailed prior medication trials, and requested CPT code(s) for prior authorization.
    SourceLink
    On This Page
    Coverage Criteria for rTMSDiagnosis and Procedure CodesProvider Requirements and Authorization ActionsLevel of Care SettingsTreatment ModalitiesKey DefinitionsBackground
  1. Provide documentation of at least two adequate trials of psychopharmacologic agents during the current depressive episode from at least two different medication classes, each trial of at least six weeks at therapeutic dose, with assessment results from standardized rating scales (GDS, PHQ‑9, BDI, HAM‑D, MADRS, QIDS, or IDS‑SR).
  2. If medication intolerance is claimed, document trials of four psychopharmacologic agents from at least two different classes (at least one an antidepressant) with distinct side effects explaining intolerance.
  3. Alternative Capital clinical vignette thresholds (document as applicable): lack of response to four trials from two classes; or lack of response to three trials from two classes plus one augmenting agent; or history of positive response to prior TMS (≥ 6 months since prior course); or currently receiving ECT with TMS considered a less invasive alternative.
  4. Documentation Required

    Required Documentation for Authorization

    Submit all required documentation with the prior authorization request. Incomplete documentation may delay or result in denial of authorization.

    • Completed rTMS request form with member and provider information, member name/ID/date of birth, and proposed treatment start date.
    • Confirmed diagnosis: severe Major Depressive Disorder (F32.2 or F33.2) with date and pretreatment rating scale scores (GDS, PHQ‑9, BDI, HAM‑D, MADRS, QIDS, or IDS‑SR).
    • Detailed medication history table listing prior medication trials (name, dosage, dates, response) and standardized rating scale results demonstrating lack of clinically significant response when applicable.
    • Description of prior TMS and/or ECT treatments in the past three years, including dates and response.
    • Clinical narrative including current symptoms/mental status, history of depression, therapy history, support system, and risk/benefit analysis supporting rTMS.
    • Documentation supporting any claimed medication intolerance or other clinical exceptions (e.g., prior positive TMS response, concurrent ECT rationale).
    • Evidence the ordering physician meets experience/supervision requirements and that the treating facility/practitioner meets applicable licensure/credentialing requirements.
    Denial Risk

    Triggers for Denial

    Failure to provide required prior medication trial documentation, pretreatment rating scales, confirmed diagnosis, or the completed rTMS request form may result in denial of the request.

    • Missing documentation of at least two adequate medication trials from different classes (or alternative documented criteria) is a common trigger for denial.
    • Omitting pretreatment standardized depression rating scores or lacking dates/duration/doses for prior medications may lead to denial.
    • If the ordering provider or facility credentials/experience are not documented, authorization may be denied.
    90868Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment - subsequent delivery and management, per session.
    90869Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment - subsequent motor threshold redetermination with delivery and management.